Correspondence 0001628280-23-014165 from Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120) (AVTX)
Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120)
Date: April 28, 2023 · CIK: 0001534120 · Accession: 0001628280-23-014165
AI Filing Summary & Sentiment
File numbers found in text: 333-271225
Letter
Document
540 Gaither Road, Suite 400
Rockville, MD 20850
April 28, 2023
VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, DC 20549
Attention: Joshua Gorsky
Division of Corporation Finance
Office of Life Sciences
Re: Avalo Therapeutics, Inc.
Registration Statement on Form S-3
Filed April 12, 2023
File No. 333-271225
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Avalo Therapeutics, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to accelerate the effective date of the above-referenced registration statement (the “Registration Statement”) so as to become effective on Tuesday, May 2, 2023, at 4:15 p.m. Eastern Time, or as soon thereafter as practicable.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Alexander M. Donaldson at (919) 781-4000. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to Mr. Donaldson via email at adonaldson@wyrick.com.
Very truly yours,
AVALO THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm Document 540 Gaither Road, Suite 400 Rockville, MD 20850 April 28, 2023 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, DC 20549 Attention: Joshua Gorsky Division of Corporation Finance Office of Life Sciences Re: Avalo Therapeutics, Inc. Registration Statement on Form S-3 Filed April 12, 2023 File No. 333-271225 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Avalo Therapeutics, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to accelerate the effective date of the above-referenced registration statement (the “Registration Statement”) so as to become effective on Tuesday, May 2, 2023, at 4:15 p.m. Eastern Time, or as soon thereafter as practicable. Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Alexander M. Donaldson at (919) 781-4000. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to Mr. Donaldson via email at adonaldson@wyrick.com. Very truly yours, AVALO THERAPEUTICS, INC. By: /s/ Christopher Sullivan Christopher Sullivan Chief Financial Officer cc: Alexander M. Donaldson, Wyrick Robbins Yates & Ponton LLP